65results about How to "Improve pathological damage" patented technology

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

The invention discloses bifidobacterium bifidum CCFM1063 and application thereof. The bifidobacterium bifidum CCFM1063 can be rapidly planted in an intestinal tract, fasting blood-glucose and oral glucose tolerance caused by type II diabetes is significantly improved, and the area under the curve for glucose tolerance is reduced; total cholesterol in a serum increased and high-density lipoproteincholesterol reduced caused by the type II diabetes are significantly improved; the condition of insulin resistance caused by the significantly improved is significantly improved; the level of inflammation in type II diabetes liver tissue is significantly improved; pathological injuries of tissue such as pancreas and liver caused by the type II diabetes are significantly improved; the bifidobacterium bifidum CCFM1063 has higher adsorption capacity on perfluoro caprylic acid, and has the capacity of relieving toxicity of the perfluoro caprylic acid; and the constipation condition caused by the type II diabetes is significantly improved and the level of Allobaculum genus in the intestinal tract is improved, and functions of relieving anxiety and depression and colonitis are achieved.

The invention discloses application of curcumin to preparation of drugs for treating cerebral ischemia / reperfusion injuries, belonging to the technical field of drug preparation. A cerebral ischemia / reperfusion injury model is prepared and curcumin-PVP (polyvinylpyrrolidone) solid dispersions are used for treating the disease model after being dissolved with the saline for injection. Results show that curcumin can obviously improve the injuries of vital organs such as distant livers and kidneys caused by cerebral tissue injuries and cerebral ischemia / reperfusion injuries and can control the expression levels of several factors related to apoptosis, inflammations and oxidation, control further aggravation of the injuries and protect the vital organs such as cerebral tissues and livers and kidneys.

The invention relates to a novel application of niclosamide ethanolamine salt, and in particular to the application of the niclosamide ethanolamine salt in preparing medicines for preventing and treating diabetes type 1 and complications thereof; and the invention also conducts studies on the protective effect and the action mechanism of the niclosamide ethanolamine salt on the diabetes type 1 and the complications thereof. Results show that the niclosamide ethanolamine salt can improve symptoms of polyuria, polydipsia and polyphagia in a mouse with the diabetes type 1, reduce blood glucose, glycosylated hemoglobin and urine glucose levels, increase a serum insulin level and improve pancreas pathological damage. In the aspect of protecting a kidney target organ, the niclosamide ethanolamine salt can reduce a urinary albumin excretion rate, lower a creatinine clearance rate, diminish the area of glomerular vascular loops, reduce NAG and NGAL discharge in urine and inhibit activation of Akt / mTOR / 4E-BP1 signaling pathways in kidney tissues. In addition, the niclosamide ethanolamine salt can also take an obvious protecting effect on liver and achieve a significant improving effect on muscle functions. Therefore, the niclosamide ethanolamine salt has a significant protective effect on the diabetes type 1 and the complications thereof.

The invention provides an application of astaxanthin and a composition in preparing medicine for treating glomerular mesangial lesions. The adopted astaxanthin and composition are of an all-trans-isomer-oriented sinistrality structure, and the medicine is in an oral medication dosage form. Oral absorption promoter can be added or not added in the medicine preparation process of the astaxanthin or derivatives. One kind or any several kinds or all of the oral absorption promoter is added, and the any several kinds or all the oral absorption promoter is added according to any proportion. After the medicine is used by an IgA nephritic patient, it is observed that after the astaxanthin and the composition are taken, 24HUP is remarkably reduced, Scr tends to be increased, eGFR tends to be reduced, and the changes of 24HUP, Scr and eGFR all have statistical significance. After the medicine is adopted, AIba and TG are different in overall data, no change trend is found, and no remarkable change of Tchol or HDL-c or LDL-c is observed.

The invention provides a novel coronavirus main protease inhibitor as well as a preparation method and application thereof. Specifically provided is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or an isotope substitution form thereof. The compound can be used for effectively inhibiting the activity of SARS-CoV-2 Mpro, and can be used for preparing an SARS-CoV-2 Mpro inhibitor to block the replication and transcription of SARS-CoV-2 virus in the body of a patient. The compound disclosed by the invention has a very good application prospect in the preparation of an SARS-CoV-2 Mpro inhibitor, an SARS-CoV-2 resisting medicine and a medicine for preventing and / or treating novel coronavirus pneumonia.

The invention relates to the technical field of medicine, in particular to the application of notoginseng. The invention discloses the use of notoginseng and its pharmaceutically acceptable salt or plant extract containing notoginseng in the preparation of medicines or health care products for preventing or treating ulcerative colitis. The present invention finds for the first time that panax notoginseng can significantly improve symptoms such as weight loss, bloody stool, colon shortening, and histopathological damage in mice with experimental ulcerative colitis, providing a new option for clinical treatment of ulcerative colitis, and has a good application prospect .

The invention relates to the technical field of microorganisms, and discloses a lactobacillus reuteri and its application. The preservation number of Lactobacillus reuteri CCFM8631 of the present invention is CGMCC No.14394, which can significantly improve the level of rat peripheral blood neurotransmitter 5-serotonin; restore the rat peripheral blood testosterone hormone level caused by a high-sugar and high-fat diet and the abnormal abundance of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora; tolerance to simulated gastrointestinal fluid, rapid colonization in the intestinal tract, significantly improved the liver of rats with metabolic syndrome caused by high-sugar and high-fat diet , pathological damage of the duodenum and elevated levels of triglyceride and total cholesterol in serum, used to prevent, slow down or treat metabolic disorders such as metabolic syndrome, irritable bowel syndrome and anxiety and depression related to metabolic syndrome and other mental illness.